MX2023009037A - Compuesto de pirimidopirano. - Google Patents
Compuesto de pirimidopirano.Info
- Publication number
- MX2023009037A MX2023009037A MX2023009037A MX2023009037A MX2023009037A MX 2023009037 A MX2023009037 A MX 2023009037A MX 2023009037 A MX2023009037 A MX 2023009037A MX 2023009037 A MX2023009037 A MX 2023009037A MX 2023009037 A MX2023009037 A MX 2023009037A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- pyrimidopyran
- iii
- represented
- formula
- Prior art date
Links
- -1 Pyrimidopyran compound Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente solicitud se refiere a un compuesto de pirimidopirano, y describe específicamente un compuesto como se representa mediante la fórmula (III), y una sal farmacéuticamente aceptable del mismo. (ver Fórmula).
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110139674 | 2021-02-01 | ||
| CN202110258547 | 2021-03-09 | ||
| CN202110706033 | 2021-06-24 | ||
| CN202210070174 | 2022-01-20 | ||
| PCT/CN2022/074390 WO2022161443A1 (zh) | 2021-02-01 | 2022-01-27 | 嘧啶并吡喃类化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009037A true MX2023009037A (es) | 2023-08-10 |
Family
ID=82653023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009037A MX2023009037A (es) | 2021-02-01 | 2022-01-27 | Compuesto de pirimidopirano. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250066387A9 (es) |
| EP (1) | EP4286378A4 (es) |
| JP (1) | JP7762985B2 (es) |
| KR (1) | KR20230138509A (es) |
| CN (1) | CN116761799A (es) |
| AU (1) | AU2022212151B2 (es) |
| BR (1) | BR112023015359A2 (es) |
| CA (1) | CA3207058A1 (es) |
| IL (1) | IL304845A (es) |
| MX (1) | MX2023009037A (es) |
| TW (1) | TWI793999B (es) |
| WO (1) | WO2022161443A1 (es) |
| ZA (1) | ZA202308002B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023284881A1 (en) * | 2021-07-16 | 2023-01-19 | Silexon Ai Technology Co., Ltd. | Heterocyclic compounds useful as kras g12d inhibitors |
| MX2024008987A (es) * | 2022-01-21 | 2024-09-10 | D3 Bio Wuxi Co Ltd | Derivado de heteroaril-pireno sustituido por anillo puenteado, y uso del mismo. |
| WO2023198078A1 (zh) * | 2022-04-11 | 2023-10-19 | 杭州英创医药科技有限公司 | 作为kras g12d抑制剂的多环化合物 |
| WO2024064335A1 (en) * | 2022-09-23 | 2024-03-28 | Ikena Oncology, Inc. | Naphthyl-substituted pyranopyrimidinones and related compounds and their use in treating medical conditions |
| KR20250161633A (ko) * | 2023-03-23 | 2025-11-17 | 디3 바이오 (우씨) 컴퍼니, 리미티드 | 헤테로고리 치환된 피리미도피란 화합물 및 이의 용도 |
| WO2025195335A1 (en) * | 2024-03-18 | 2025-09-25 | D3 Bio (Wuxi) Co., Ltd. | Heterocyclic substituted pyrimidopyran compounds and their applications |
| WO2025026903A1 (en) | 2023-07-31 | 2025-02-06 | Bayer Aktiengesellschaft | Imidazo pyrimidine compounds for the treatment of cancer |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250204849A1 (en) * | 2023-12-22 | 2025-06-26 | Sleepdev, Inc. | Therapeutic methods for sleep respiratory issues via a positional therapy device that monitors a users's head position |
| WO2025232765A1 (en) * | 2024-05-07 | 2025-11-13 | D3 Bio (Wuxi) Co., Ltd. | Treatment of cancer with pyrimidoheterocyclic compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017266911B2 (en) | 2016-05-18 | 2021-09-02 | Array Biopharma, Inc. | KRas G12C inhibitors |
| EP3710439B1 (en) * | 2017-11-15 | 2023-02-15 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| CA3086867A1 (en) * | 2018-08-16 | 2020-02-20 | F. Hoffmann-La Roche Ag | Fused ring compounds as ras protein inhibitors |
| WO2020239123A1 (zh) * | 2019-05-31 | 2020-12-03 | 上海翰森生物医药科技有限公司 | 芳香杂环类衍生物调节剂、其制备方法和应用 |
| CN112390788A (zh) * | 2019-08-13 | 2021-02-23 | 苏州闻天医药科技有限公司 | 一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途 |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| JP7480298B2 (ja) * | 2019-12-02 | 2024-05-09 | シャンハイ インリー ファーマシューティカル カンパニー リミテッド | 酸素含有複素環化合物、その製造方法及び使用 |
| CN117050079A (zh) * | 2020-03-12 | 2023-11-14 | 德昇济医药(无锡)有限公司 | 嘧啶并杂环类化合物及其应用 |
-
2022
- 2022-01-27 US US18/275,178 patent/US20250066387A9/en active Pending
- 2022-01-27 EP EP22745316.4A patent/EP4286378A4/en active Pending
- 2022-01-27 TW TW111103778A patent/TWI793999B/zh active
- 2022-01-27 WO PCT/CN2022/074390 patent/WO2022161443A1/zh not_active Ceased
- 2022-01-27 MX MX2023009037A patent/MX2023009037A/es unknown
- 2022-01-27 AU AU2022212151A patent/AU2022212151B2/en active Active
- 2022-01-27 CN CN202280012164.9A patent/CN116761799A/zh active Pending
- 2022-01-27 CA CA3207058A patent/CA3207058A1/en active Pending
- 2022-01-27 JP JP2023546247A patent/JP7762985B2/ja active Active
- 2022-01-27 KR KR1020237029569A patent/KR20230138509A/ko active Pending
- 2022-01-27 BR BR112023015359A patent/BR112023015359A2/pt unknown
-
2023
- 2023-07-30 IL IL304845A patent/IL304845A/en unknown
- 2023-08-17 ZA ZA2023/08002A patent/ZA202308002B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL304845A (en) | 2023-09-01 |
| KR20230138509A (ko) | 2023-10-05 |
| AU2022212151A1 (en) | 2023-08-17 |
| US20250066387A9 (en) | 2025-02-27 |
| CA3207058A1 (en) | 2022-08-04 |
| WO2022161443A1 (zh) | 2022-08-04 |
| JP7762985B2 (ja) | 2025-10-31 |
| US20240327433A1 (en) | 2024-10-03 |
| AU2022212151B2 (en) | 2025-01-23 |
| ZA202308002B (en) | 2024-08-28 |
| EP4286378A4 (en) | 2024-08-07 |
| EP4286378A1 (en) | 2023-12-06 |
| BR112023015359A2 (pt) | 2023-11-14 |
| TWI793999B (zh) | 2023-02-21 |
| JP2024504831A (ja) | 2024-02-01 |
| CN116761799A (zh) | 2023-09-15 |
| TW202233630A (zh) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202308002B (en) | Pyrimidopyran compound | |
| ZA202206923B (en) | New methylquinazolinone derivatives | |
| MX2025003665A (es) | Derivados macrociclicos y las aplicaciones de estos | |
| ZA202104112B (en) | 15-pgdh inhibitor | |
| TN2011000286A1 (en) | Spiroheterocyclic n-oxypiperidines as pesticides | |
| MY147211A (en) | Novel dihydropseudoerythromycin derivatives | |
| MX2024015714A (es) | Compuesto de pirimidopirano sustituido heterocíclico y uso de este | |
| MX2021007140A (es) | Compuesto para usarse en enfermedades de la retina. | |
| ZA202213152B (en) | Novel acid secretion inhibitor and use thereof | |
| ZA202309546B (en) | Agrochemical composition of solid state form of pyroxasulfone | |
| PH12022550777A1 (en) | Compound as small molecule inhibitor pd-1/pd-l1 and application thereof | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| TN2021000025A1 (en) | Novel heterocyclic amine derivative and pharmaceutical composition comprising same | |
| PH12015502684B1 (en) | New compounds having triple activities of thrombolysis, antithrombotic and radical scavenging, and synthesis, nano-structure and use thereof | |
| WO2015042414A8 (en) | Multicyclic compounds and methods of using same | |
| SG11201810725WA (en) | Novel β-lactamase inhibitors | |
| SG11201907945YA (en) | Azetidine derivative | |
| MY152557A (en) | 3-aminocyclopentanecarboxamides as chemokine receptor modulators | |
| MX2024005066A (es) | Compuestos de cd73. | |
| SG10201406839VA (en) | Benzazepine compound | |
| WO2020016302A8 (en) | A xinafoate salt of a jak inhibiting compound | |
| ZA202205170B (en) | Process and intermediate for the preparation of oxetan-2-ylmethanamine | |
| AU2021239631A8 (en) | Oxadiazole derivative | |
| ZA202402507B (en) | Tricyclic polypeptide conjugated drug and use thereof | |
| MX2023013803A (es) | Sal farmaceuticamente aceptable del derivado de pirazoloheteroarilo y forma cristalina del mismo. |